Table Graph
      published meta-analysis   sensitivity analysis   studies

complete primary vaccine series in COVID-19 prophylaxis (excluding children) - Summary of results

OutcomeTE95% CInkI2ROBPub. bias deathsdetailed resultsOut of scaleMcConeghy, 2022 (REV) 33.33 [9.62; 115.47] 33.33[9.62; 115.47]McConeghy, 2022 (REV)10%NAnot evaluable hospitalization or deathdetailed resultsMcConeghy, 2022 (REV) 5.56 [2.03; 15.21] 5.56[2.03; 15.21]McConeghy, 2022 (REV)10%NAnot evaluable confirmed COVID (any severity)detailed resultsKislaya, 2022 (REV) 3.23 [1.86; 5.59] Mattiuzzi, 2022 (REV) 2.86 [2.62; 3.11] McConeghy, 2022 (REV) 2.04 [1.43; 2.91] Tan, 2022 (REV) 7.14 [2.66; 19.21] 2.84[2.13; 3.78]Kislaya, 2022 (REV), Mattiuzzi, 2022 (REV), McConeghy, 2022 (REV), Tan, 2022 (REV)457%NAnot evaluable hospitalizationdetailed resultsMattiuzzi, 2022 (REV) 3.23 [2.28; 4.56] McConeghy, 2022 (REV) 1.92 [0.28; 13.28] Tan, 2022 (REV) 21.28 [11.84; 38.24] Tenforde, 2022 (REV) 5.49 [2.82; 10.68] 5.86[2.06; 16.65]Mattiuzzi, 2022 (REV), McConeghy, 2022 (REV), Tan, 2022 (REV), Tenforde, 2022 (REV)490%387,230NAnot evaluable ICU admissiondetailed resultsMattiuzzi, 2022 (REV) 3.03 [0.74; 12.45] 3.03[0.74; 12.45]Mattiuzzi, 2022 (REV)10%NAnot evaluable severe COVID-19 occurrencedetailed resultsTan, 2022 (REV) 12.82 [1.80; 91.48] 12.82[1.80; 91.48]Tan, 2022 (REV)10%NAnot evaluable0.520.01.0relative treatment effectwww.metaEvidence.org2024-09-27 21:57 +02:00

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;

pathologies: 89 - treatments: 1317 - roots T: 290

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons